Kinzbio develops phage-based precision antimicrobials to combat antibiotic-resistant infections quickly and effectively. Their platform utilizes AI-driven software and proprietary databases to deliver personalized, pharmaceutical-grade therapies within 5 to 15 days. The company also engineers solutions for infection prevention in clinical settings, targeting harmful bacteria with high specificity.
Funding
Funding not disclosed
Founders
Product
Problem
Antibiotic-resistant infections pose a significant global health challenge, requiring more targeted and effective therapeutic interventions. Traditional antimicrobial approaches often lack specificity, leading to collateral damage to beneficial microbiota and contributing to the development of further resistance.
Solution
Kinzbio develops precision antimicrobial therapies utilizing bacteriophages, naturally occurring viruses that infect and kill specific bacteria. Their platform leverages proprietary phage databases, AI-driven software, and patent-protected technologies to rapidly identify and optimize phages tailored to individual bacterial pathogens. This enables the delivery of pharmaceutical-grade, personalized treatments within 5-15 days for a range of infections, including those in hospital and ICU settings. The highly specific nature of phage therapy ensures that only target bacteria are eliminated, preserving the patient's microbiome.
Target Audience
Kinzbio targets healthcare providers, including hospitals and intensive care units, seeking advanced solutions for antibiotic-resistant infections, as well as pharmaceutical companies interested in collaborative development of phage-based therapeutics.
Features
- Bacteriophage-based therapeutic development platform for targeted antimicrobial treatment.
- Proprietary databases and biobanks for comprehensive phage strain collection and characterization.
- AI-driven software for rapid identification and optimization of bacteriophages against specific bacterial pathogens.
- Personalized therapy development with a turnaround time of 5-15 days.
- Pharmaceutical-grade manufacturing capabilities for clinical applications.
- Development of phage-based solutions for infection prevention in healthcare settings.
- Highly specific bacterial targeting, minimizing impact on beneficial commensal bacteria.
- Adaptable platform designed to address emerging resistance mechanisms.